156 related articles for article (PubMed ID: 23494176)
1. High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.
Gu Y; Pan Y; Meng B; Guan B; Fu K; Sun B; Zheng F
Tumour Biol; 2013 Jun; 34(3):1441-50. PubMed ID: 23494176
[TBL] [Abstract][Full Text] [Related]
2. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
3. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
4. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics of high-grade B-cell lymphomas with rearrangement of MYC, bcl-6 and bcl-2].
Gong JY; Zhang YZ; Zhang JD; Zhang W; Li JQ; Ru K; Liu EB
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):14-18. PubMed ID: 29325245
[No Abstract] [Full Text] [Related]
6. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
[TBL] [Abstract][Full Text] [Related]
7. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
Shen X; Zhou LT; Li AQ; Yi HM; Ouyang BS; Xu HM; Xie JL; Gu YJ; Zhang L; Dong L
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):120-125. PubMed ID: 35152630
[No Abstract] [Full Text] [Related]
9. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
11. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement.
Kelemen K; Holden J; Johnson LJ; Davion S; Robetorye RS
Cytometry B Clin Cytom; 2017 Jul; 92(4):310-314. PubMed ID: 26517296
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
14. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
15. [Significance of C-myc expression in T-lymphoblastic lymphoma/leukemia and its relation with prognosis].
Zhang Y; Li J; Xi Y; Bai W; Bai W; Sun R
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):571-7. PubMed ID: 26705181
[TBL] [Abstract][Full Text] [Related]
16. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].
Sun GX; Cao XS; Li Q; Wang ZL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):576-81. PubMed ID: 23042398
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
[Next] [New Search]